A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–347. doi: 10.1016/j.ejca.2021.07.039
   PubMed Web of Science ®Google Scholar
• Lyall M, Crawford R, Bell T, et al. Characterizing the patient journey in multiple myeloma: qualitative review. JMIR Cancer. 2022;8(3):e39068. doi: 10.2196/39068
   PubMedGoogle Scholar
• Fonseca R, Tran D, Laidlaw A, et al. Impact of disease progression, line of therapy, and response on health-related quality of life in multiple myeloma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2023;23(6):426–37.e11. doi: 10.1016/j.clml.2023.03.005
   PubMed Web of Science ®Google Scholar
• Mejia Saldarriaga M, Darwiche W, Jayabalan D, et al. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Front Oncol. 2022;12:1020011. doi: 10.3389/fonc.2022.1020011
   PubMed Web of Science ®Google Scholar
• Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee. Blood Cancer J. 2022;12(6):98. doi: 10.1038/s41408-022-00695-5
   PubMed Web of Science ®Google Scholar
• Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109. doi: 10.1038/s41408-018-0141-0
   PubMed Web of Science ®Google Scholar
• Snowden JA, Greenfield DM, Bird JM, et al. Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Br J Haematol. 2017;176(6):888–907. doi: 10.1111/bjh.14514
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Alsina M, et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Canc Netw. 2018;16(1):11–20. doi: 10.6004/jnccn.2018.0002
   PubMed Web of Science ®Google Scholar
• Callander NS, Baljevic M, Adekola K, et al. NCCN guidelines insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8–19. doi: 10.6004/jnccn.2022.0002
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2021;32(3):309–322. doi: 10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi: 10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers (Basel). 2021;13(9):2018. doi: 10.3390/cancers13092018
   PubMed Web of Science ®Google Scholar
• Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565–1575. doi: 10.1172/JCI129205
   PubMed Web of Science ®Google Scholar
• Swamydas M, Murphy EV, Ignatz-Hoover JJ, et al. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol. 2022;15(1):17. doi: 10.1186/s13045-022-01234-2
   PubMed Web of Science ®Google Scholar
• Yamamoto L, Amodio N, Gulla A, et al. Harnessing the immune system against multiple myeloma: challenges and opportunities. Front Oncol. 2020;10:606368. doi: 10.3389/fonc.2020.606368
   PubMed Web of Science ®Google Scholar
• Martin T, Strickland S, Glenn M, et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 2019;9(4):41. doi: 10.1038/s41408-019-0198-4
   PubMed Web of Science ®Google Scholar
• sanofi-aventis U.S. LLC. SARCLISA (isatuximab-irfc) injection, for intravenous use - prescribing information. [cited 2023 Feb 21]. Available at: https://products.sanofi.us/Sarclisa/sarclisa.pdf
   Google Scholar
• Sanofi Winthrop Industrie. Sarclisa - summary of product characteristics. [cited Feb 21]. Available at: https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf
   Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107. doi: 10.1016/S0140-6736(19)32556-5
   PubMed Web of Science ®Google Scholar
• Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022;23(3):416–427. doi: 10.1016/S1470-2045(22)00019-5
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371. doi: 10.1016/S0140-6736(21)00592-4
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos MAC, Mikhael J, et al. VP5-2022: updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (isa-kd) vs kd in relapsed multiple myeloma (MM). Ann Oncol. 2022;33(6):664–665. doi: 10.1016/j.annonc.2022.04.013
   Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221. doi: 10.1016/S1470-2045(19)30788-0
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198–4212. doi: 10.1002/cncr.33809
   PubMed Web of Science ®Google Scholar
• Nooka AK, Cohen A, Lee HC, et al. Single-Agent Belantamab Mafodotin in patients with relapsed or refractory multiple myeloma: final analysis of the DREAMM-2 trial. Blood. 2022;140(Supplement 1):7301–7303. abstract 3246. doi: 10.1182/blood-2022-164877
   Google Scholar
• Suvannasankha A, Bahlis NJ, Trudel S, et al. Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 study. J Clin Oncol. 2022;40(16_suppl):8018. doi: 10.1200/JCO.2022.40.16_suppl.8018
   Web of Science ®Google Scholar
• Quach H, Gironella M, Lee C, et al. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis. J Clin Oncol. 2022;40(16_suppl):8017. doi: 10.1200/JCO.2022.40.16_suppl.8017
   Web of Science ®Google Scholar
• Popat R, Nooka A, Stockerl-Goldstein K, et al. DREAMM-6: safety, tolerability and clinical activity of Belantamab Mafodotin (Belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):19–20. doi: 10.1182/blood-2020-139332
   Google Scholar
• Trudel S, McCurdy A, Fu M, et al. Belantamab Mafodotin in combination with pomalidomide and dexamethasone demonstrates durable responses in triple class exposed/refractory multiple myeloma. Blood. 2022;140(Supplement 1):7306–7307. abstract 3248. doi: 10.1182/blood-2022-160445
   Google Scholar
• Shragai T, Magen H, Lavi N, et al. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol. 2023;200(1):45–53. doi: 10.1111/bjh.18479
   PubMed Web of Science ®Google Scholar
• Vassilopoulos S, Vassilopoulos A, Kalligeros M, et al. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(11):ofac574. doi: 10.1093/ofid/ofac574
   PubMed Web of Science ®Google Scholar
• Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–3187. doi: 10.1158/1078-0432.CCR-18-1597
   PubMed Web of Science ®Google Scholar
• Nooka AK, Gleason C, Sargeant MO, et al. Managing infusion reactions to new monoclonal antibodies in multiple myeloma: Daratumumab and Elotuzumab. J Oncol Pract. 2018;14(7):414–422. doi: 10.1200/JOP.18.00143
   PubMed Web of Science ®Google Scholar
• Quach H, Parmar G, Ocio E, et al. Subcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (pd) in patients with relapsed/refractory multiple myeloma (RRMM): interim phase 1b study results. J Clin Oncol. 2022;40(16_suppl):8025. doi: 10.1200/JCO.2022.40.16_suppl.8025
   Web of Science ®Google Scholar
• Schjesvold FH, Richardson PG, Facon T, et al. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2021;106(4):1182–1187. doi: 10.3324/haematol.2020.253450
   PubMed Web of Science ®Google Scholar
• Facon T, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022;40(5):1020–1029. doi: 10.1002/hon.3038
   PubMed Web of Science ®Google Scholar
• Schjesvold F, Bringhen S, GR P, et al. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Am J Hematol. 2021;96(11):E423–E7. doi: 10.1002/ajh.26319
   PubMed Web of Science ®Google Scholar
• Richardson PG, Harrison SJ, Bringhen S, et al. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the phase III ICARIA-MM study. Future Oncol. 2021;17(34):4797–4812. doi: 10.2217/fon-2021-0568
   PubMed Web of Science ®Google Scholar
• Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022;109(5):504–512. doi: 10.1111/ejh.13835
   PubMed Web of Science ®Google Scholar
• Capra M, Martin T, Moreau P, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica. 2022;107(6):1397–1409. doi: 10.3324/haematol.2021.279229
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Augustson B, et al. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol. 2023;98(1):E15–E9. doi: 10.1002/ajh.26602
   PubMed Web of Science ®Google Scholar
• Martin TG, Capra M, Mohty M, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma: IKEMA subgroup analysis by prior transplantation. Transplant Cell Ther. 2023;29(2):134 e1–e7 . doi: 10.1016/j.jtct.2022.11.005
   PubMedGoogle Scholar
• Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120–131. doi: 10.1111/bjh.17499
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021;35(2):562–572. doi: 10.1038/s41375-020-0868-z
   PubMed Web of Science ®Google Scholar
• Bringhen S, Pour L, Vorobyev V, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leuk Res. 2021;104:106576. doi: 10.1016/j.leukres.2021.106576
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Karanes C, Bensinger WI, et al. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021;35(12):3526–3533. doi: 10.1038/s41375-021-01262-w
   PubMed Web of Science ®Google Scholar
• Mikhael J, Richter J, Vij R, et al. A dose-finding phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia. 2020;34(12):3298–3309. doi: 10.1038/s41375-020-0857-2
   PubMed Web of Science ®Google Scholar
• Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11(5):89. doi: 10.1038/s41408-021-00478-4
   PubMed Web of Science ®Google Scholar
• Sunami K, Suzuki K, Ri M, et al. Isatuximab monotherapy in relapsed/refractory multiple myeloma: a Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Sci. 2020;111(12):4526–4539. doi: 10.1111/cas.14657
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Bringhen S, Anttila P, et al. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2021;137(9):1154–1165. doi: 10.1182/blood.2020008209
   PubMed Web of Science ®Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25):3294–3303. doi: 10.1182/blood-2016-09-740787
   PubMed Web of Science ®Google Scholar
• Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019;134(2):123–133. doi: 10.1182/blood-2019-02-895193
   PubMed Web of Science ®Google Scholar
• Djebbari F, Rampotas A, Vallance G, et al. Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: results of a UK-Wide real-world dataset. Hemasphere. 2022;6(6):e738. doi: 10.1097/HS9.0000000000000738
   PubMed Web of Science ®Google Scholar
• Djebbari F, Rampotas A, Vallance G, et al. Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: initial results of a UK-wide real-world study. Hematology. 2022;27(1):691–699. doi: 10.1080/16078454.2022.2082725
   PubMed Web of Science ®Google Scholar
• Martin TG, Shah N, Richter J, et al. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021;127(11):1816–1826. doi: 10.1002/cncr.33448
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use. [cited 2023 Feb 22]. Available at: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Blenrep/pdf/BLENREP-PI-MG.PDF
   Google Scholar
• GlaxoSmithKline. BLENREP summary of product characteristics. [cited Feb 22, 2023]. Available at: https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf
   Google Scholar
• Richardson PG, Lee HC, Abdallah AO, et al. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020;10(10):106. doi: 10.1038/s41408-020-00369-0
   PubMed Web of Science ®Google Scholar
• Farooq AV, Degli Esposti S, Popat R, et al. Corneal epithelial findings in patients with multiple myeloma treated with Antibody-Drug Conjugate Belantamab Mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020;9(4):889–911. doi: 10.1007/s40123-020-00280-8
   PubMed Web of Science ®Google Scholar
• Lonial S, Nooka AK, Thulasi P, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021;11(5):103. doi: 10.1038/s41408-021-00494-4
   PubMed Web of Science ®Google Scholar
• Eaton JS, Miller PE, Mannis MJ, et al. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31(10):589–604. doi: 10.1089/jop.2015.0064
   PubMed Web of Science ®Google Scholar
• Baines AC, Ershler R, Kanapuru B, et al. FDA approval summary: Belantamab Mafodotin for patients with relapsed or refractory multiple myeloma. Clin Cancer Res. 2022;28(21):4629–4633. doi: 10.1158/1078-0432.CCR-22-0618
   PubMed Web of Science ®Google Scholar
• Ferron-Brady G, Rathi C, Collins J, et al. Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed/refractory multiple myeloma. Clin Pharmacol Ther. 2021;110(5):1282–1292. doi: 10.1002/cpt.2409
   PubMed Web of Science ®Google Scholar
• Usmani S, Alonso A, Quach H, et al. DREAMM-9: phase I study of belantamab mafodotin plus standard of care in patients with transplant-ineligible newly diagnosed multiple myeloma. Hemasphere. 2022;6(Suppl):19. abstract P4. doi: 10.1097/01.HS9.0000829628.48136.02
   Google Scholar
• Wahab A, Rafae A, Mushtaq K, et al. Ocular toxicity of Belantamab Mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol. 2021;11:678634. doi: 10.3389/fonc.2021.678634
   PubMed Web of Science ®Google Scholar
• Popat R, Warcel D, O’Nions J, et al. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020;105(5):e261–e3. doi: 10.3324/haematol.2019.235937
   PubMed Web of Science ®Google Scholar
• Mohan M, Rein LE, Thalambedu N, et al. Corneal toxicity with belantamab mafodotin: multi-institutional real-life experience. Am J Hematol. 2022;97(12):E451–E3. doi: 10.1002/ajh.26728
   PubMed Web of Science ®Google Scholar
• Vaxman I, Abeykoon J, Dispenzieri A, et al. “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the mayo clinic experience. Blood Cancer J. 2021;11(12):196. doi: 10.1038/s41408-021-00592-3
   PubMed Web of Science ®Google Scholar
• Alegre A, Benzo G, Alonso R, et al. Real-world outcomes of Belantamab Mafodotin for relapsed/refractory multiple myeloma (RRMM): preliminary results of a Spanish Expanded access program (EAP). Oncol Ther. 2023;11(1):83–96. doi: 10.1007/s40487-022-00212-5
   PubMed Web of Science ®Google Scholar
• Iula R, De Novellis D, Trastulli F, et al. Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: a multicentric real-life experience. Front Oncol. 2022;12:1026251. doi: 10.3389/fonc.2022.1026251
   PubMed Web of Science ®Google Scholar
• Bausell RB, Soleimani A, Vinnett A, et al. Corneal changes after Belantamab Mafodotin in multiple myeloma patients. Eye Contact Lens. 2021;47(6):362–365. doi: 10.1097/ICL.0000000000000768
   PubMed Web of Science ®Google Scholar
• Chuang K, Pineda R, Liu S. Belantamab mafodotin associated corneal microcyst-like epithelial changes. Am J Ophthalmol Case Rep. 2022;25:101392. doi: 10.1016/j.ajoc.2022.101392
   PubMedGoogle Scholar
• Rousseau A, Michot JM, Labetoulle M. Belantamab mafotodin-induced epithelial keratopathy masquerading myopic surgery. Ophthalmol. 2020;127(12):1626. doi: 10.1016/j.ophtha.2020.07.047
   PubMed Web of Science ®Google Scholar
• Aschauer J, Donner R, Lammer J, et al. Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy. Am J Ophthalmol. 2022;242:116–124. doi: 10.1016/j.ajo.2022.06.009
   PubMed Web of Science ®Google Scholar
• Matsumiya W, Karaca I, Ghoraba H, et al. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. Am J Ophthalmol Case Rep. 2021;23:101133. doi: 10.1016/j.ajoc.2021.101133
   PubMedGoogle Scholar
• Abeykoon JP, Vaxman J, Patel SV, et al. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. Br J Haematol. 2022;199(1):95–99. doi: 10.1111/bjh.18298
   PubMed Web of Science ®Google Scholar
• Prawitz T, Popat R, Suvannasankha A, et al. DREAMM-2: indirect comparisons of Belantamab Mafodotin vs. Selinexor + dexamethasone and standard of care Treatments in relapsed/refractory multiple myeloma. Adv Ther. 2021;38(11):5501–5518. doi: 10.1007/s12325-021-01884-7
   PubMed Web of Science ®Google Scholar
• Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985–1005. doi: 10.1038/s41375-020-0734-z
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665–674. doi: 10.1016/S0140-6736(21)01338-6
   PubMed Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. doi: 10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-Cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood. 2022;140(Supplement 1):388–390. doi: 10.1182/blood-2022-166494
   PubMedGoogle Scholar
• Bumma N, Richter J, Brayer J, et al. Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: a phase 1/2 first-in-human study. Blood. 2022;140(Supplement 1):10140–10141. abstract 4555. doi: 10.1182/blood-2022-159969
   Google Scholar
• Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–2244. doi: 10.1056/NEJMoa2204591
   PubMed Web of Science ®Google Scholar
• Chari A, Touzeau C, Schinke C, et al. Talquetamab, a G Protein-Coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): phase 1/2 results from MonumenTAL-1. Blood. 2022;140(Supplement 1):384–387. doi: 10.1182/blood-2022-159707
   Google Scholar
• Carlo-Stella C, Mazza R, Manier S, et al. RG6234, a GPRC5DxCD3 T-Cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood. 2022;140(Supplement 1):397–399. abstract 161. doi: 10.1182/blood-2022-157988
   Google Scholar
• Trudel S, Cohen AD, Krishnan AY, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138(Supplement 1):157. doi: 10.1182/blood-2021-147983
   Google Scholar
• Janssen Biotech Inc. TECVAYLI (teclistamab-cqyv) injection, for subcutaneous use. [cited 19 Jan 2023]. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf
   Google Scholar
• Janssen-Cilag International NV. TECVAYLI summary of product characteristics. [cited 2023 Mar 3]. Available at: https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf
   Google Scholar
• Pfizer Inc. ELREXFIO (elranatamab-bcmm) injection, for subcutaneous use. [cited 2023 21 Aug]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345s000lbl.pdf
   Google Scholar
• Janssen Biotech Inc. TALVEY (talquetamab-tgvs) injection, for subcutaneous use. [cited 2023 Aug 21]. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TALVEY-pi.pdf
   Google Scholar
• Wong SW, Bar N, Paris L, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell maturation antigen (BCMA) x CD3 T-Cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study. Blood. 2022;140(Supplement 1):400–402. abstract 162. doi: 10.1182/blood-2022-159009
   Google Scholar
• Voorhees PM, D’Souza A, Weisel K, et al. A phase 1 first-in-human study of abbv-383, a BCMA × CD3 bispecific T-Cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma. Blood. 2022;140(Supplement 1):4401–4404. doi: 10.1182/blood-2022-167008
   Google Scholar
• Cho SF, Yeh TJ, Anderson KC, et al. Bispecific antibodies in multiple myeloma treatment: a journey in progress. Front Oncol. 2022;12:1032775. doi: 10.3389/fonc.2022.1032775
   PubMed Web of Science ®Google Scholar
• Searle E, Quach H, Wong SW, et al. Teclistamab in combination with subcutaneous Daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a Phase1b, multicohort study. Blood. 2022;140(Supplement 1):394–396. abstract 160. doi: 10.1182/blood-2022-159711
   Google Scholar
• Rodríguez-Otero P, D’Souza A, Reece DE, et al. A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). J Clin Oncol. 2022;40(16_suppl):8032. doi: 10.1200/JCO.2022.40.16_suppl.8032
   Web of Science ®Google Scholar
• Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–2267. doi: 10.1038/s41591-023-02528-9
   PubMed Web of Science ®Google Scholar
• Grosicki S, Mellqvist U-H, Pruchniewski L, et al. Elranatamab in combination with Daratumumab for patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the phase 3 magnetismm-5 study safety lead-in cohort. Blood. 2022;140(Supplement 1):4407–4408. abstract 1921. doi: 10.1182/blood-2022-162738
   Google Scholar
• D’Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a B-Cell maturation antigen x CD3 bispecific T-Cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40(31):3576–3586. doi: 10.1200/JCO.22.01504
   PubMed Web of Science ®Google Scholar
• Boss IW, Thompson E, Gaudy AM, et al. Soluble factors correlated with high-grade cytokine release syndrome (CRS): a comparison of subcutaneous (SC) versus intravenous (IV) delivery of alnuctamab (ALNUC; BMS-986349; CC-93269) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2022;140(Supplement 1):7116–7117. doi: 10.1182/blood-2022-163192
   Google Scholar
• Costa LJ, Wong SW, Bermúdez A, et al. First clinical study of the B-Cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(Supplement 1):143. doi: 10.1182/blood-2019-122895
   Google Scholar
• van de Donk NW, Bahlis N, Mateos M-V, et al. S183: novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab. Hemasphere. 2022;6(S3):84–85. doi: 10.1097/01.HS9.0000843624.82943.92
   Google Scholar
• Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi: 10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Usmani S, Patel K, Hari P, et al. KarMMa-2 cohort 2a: efficacy and safety of Idecabtagene Vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Blood. 2022;140(Supplement 1):875–877. abstract 361. doi: 10.1182/blood-2022-162469
   PubMedGoogle Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002–1014. doi: 10.1056/NEJMoa2213614
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324. doi: 10.1016/S0140-6736(21)00933-8
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138(Supplement 1):549. doi: 10.1182/blood-2021-146060
   Google Scholar
• Cohen YC, Cohen AD, Delforge M, et al. Efficacy and safety of Ciltacabtagene Autoleucel (cilta-cel), a B-Cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-Cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Blood. 2021;138(Supplement 1):3866.
   Google Scholar
• Van De Donk NWCJ, Agha M, Cohen AD, et al. Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 cohort B 18-month follow-up. Blood. 2022;140(Supplement 1):7536–7537. abstract 3354. doi: 10.1182/blood-2022-159169
   Google Scholar
• San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335–347. doi: 10.1056/NEJMoa2303379
   PubMed Web of Science ®Google Scholar
• Mailankody S, Devlin SM, Landa J, et al. GPRC5D-Targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196–1206. doi: 10.1056/NEJMoa2209900
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi: 10.1016/j.bbmt.2018.12.758
   PubMed Web of Science ®Google Scholar
• Elmeliegy M, Viqueira A, Vandendries E, et al. Dose optimization to mitigate the risk of CRS with elranatamab in multiple myeloma. Blood. 2022;140(Supplement 1):7174–7175. doi: 10.1182/blood-2022-169971
   Google Scholar
• Trudel S, Bahlis NJ, Spencer A, et al. Pretreatment with tocilizumab prior to the CD3 bispecific cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) showed a Marked reduction in cytokine release syndrome incidence and severity. Blood. 2022;140(Suppl Supplement 1):1363–1365. doi: 10.1182/blood-2022-159381
   Google Scholar
• Lipe BC, Renaud T. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting. J Oncol Pharm Pract. 2022;29(4):1006–1010. doi: 10.1177/10781552221140320
   PubMed Web of Science ®Google Scholar
• Friedrich MJ, Neri P, Kehl N, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41(4):711–25 e6. doi: 10.1016/j.ccell.2023.02.008
   PubMed Web of Science ®Google Scholar
• Midha S, Anderson KC. Determinants of response and resistance to T cell-engaging therapies in multiple myeloma. Nat Rev Clin Oncol. 2023;20(8):505–506. doi: 10.1038/s41571-023-00775-w
   PubMed Web of Science ®Google Scholar
• Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023;7(13):3069–3074. doi: 10.1182/bloodadvances.2022009435
   PubMed Web of Science ®Google Scholar
• Cliff ERS, Reynolds G, Popat R, et al. Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma. J Clin Oncol. 2023;41(10):1949–1951. doi: 10.1200/JCO.22.02197
   PubMed Web of Science ®Google Scholar
• Sim BZ, Longhitano A, Er J, et al. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023;13(1):34. doi: 10.1038/s41408-023-00808-8
   PubMed Web of Science ®Google Scholar
• Mohan M, Nagavally S, Dhakal B, et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022;6(8):2466–2470. doi: 10.1182/bloodadvances.2021006178
   PubMed Web of Science ®Google Scholar
• Reynolds G, Cliff ERS, Mohyuddin GR, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7(19):5898–5903. doi: 10.1182/bloodadvances.2023010539
   PubMed Web of Science ®Google Scholar
• Lancman G, Parsa K, Rodriguez C, et al. Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood. 2022;140(Supplement_1):10073–10074. doi: 10.1182/blood-2022-163733
   Google Scholar
• Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746. doi: 10.1126/scitranslmed.aau7746
   PubMed Web of Science ®Google Scholar
• Narayan N, Williams B, Lipe B, et al. Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma. JAAD Case Rep. 2023;31:66–68. doi: 10.1016/j.jdcr.2022.11.013
   PubMedGoogle Scholar
• Aronson E Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma. International Myeloma Society 6th Annual Nursing Symposium; Los Angeles, CA2022. p. NS–001.
   Google Scholar
• Martin TG, Moreau P, Usmani SZ, et al. Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: patient-reported outcomes in MajesTEC-1. J Clin Oncol. 2022;40(16_suppl):8033. doi: 10.1200/JCO.2022.40.16_suppl.8033
   Web of Science ®Google Scholar
• Touzeau C, Chari A, Schinke C, et al. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody: patient-reported outcomes from MonumenTAL-1. Blood. 2022;140(Supplement 1):4447–4449. doi: 10.1182/blood-2022-162555
   Google Scholar
• Anderson Jr LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol. 2022;18(3):277–289. doi: 10.2217/fon-2021-1090
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P, Prosper F, Alfonso A, et al. CAR T-Cells in multiple myeloma are ready for prime time. J Clin Med. 2020;9(11):3577. doi: 10.3390/jcm9113577
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. ABECMA (idecabtagene vicleucel), suspension for intravenous infusion. [cited 19 Jan 2023]. Available at: https://packageinserts.bms.com/pi/pi_abecma.pdf
   Google Scholar
• Bristol-Myers Squibb Pharma EEIG. ABECMA (idecabtagene vicleucel), summary of product characteristics. [cited Feb 23, 2023]. Available at: https://www.ema.europa.eu/en/documents/product-information/abecma-epar-product-information_en.pdf
   Google Scholar
• Janssen Biotech Inc. CARVYKTI (ciltacabtagene autoleucel) suspension for intravenous infusion. [Last accessed 19 Jan 2023]. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf
   Google Scholar
• Janssen Pharmaceuticals Inc. CARVYKTI (ciltacabtagene autoleucel), summary of product characteristics. [Last accessed Feb 23, 2023]. Available at: https://www.ema.europa.eu/en/documents/product-information/carvykti-epar-product-information_en.pdf
   Google Scholar
• Dhodapkar KM, Cohen AD, Kaushal A, et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022;3(6):490–501. doi: 10.1158/2643-3230.BCD-22-0018
   PubMedGoogle Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62. doi: 10.1038/nrclinonc.2017.148
   PubMed Web of Science ®Google Scholar
• Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32. doi: 10.1038/s41408-022-00629-1
   PubMed Web of Science ®Google Scholar
• Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099–2103. doi: 10.1038/s41591-021-01564-7
   PubMed Web of Science ®Google Scholar
• Nahas GR, Komanduri KV, Pereira D, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61(4):940–943. doi: 10.1080/10428194.2019.1697814
   PubMed Web of Science ®Google Scholar
• Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359–371. doi: 10.1038/s41571-023-00754-1
   PubMed Web of Science ®Google Scholar
• Miller KC, Johnson PC, Abramson JS, et al. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022;12(10):146. doi: 10.1038/s41408-022-00741-2
   PubMed Web of Science ®Google Scholar
• Ferment B, Lambert J, Caillot D, et al. French early Nationwide Idecabtagene Vicleucel (ide-cel) chimeric antigen receptor (CAR) T-Cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): an IFM study from the descar-T registry. Blood. 2022;140(Supplement 1):4668–4670. abstract 2035. doi: 10.1182/blood-2022-162682
   Google Scholar
• Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859–866. doi: 10.1200/JCO.2017.75.5207
   PubMed Web of Science ®Google Scholar
• Karyopharm Therapeutics Inc. XPOVIO (selinexor) tablets, for oral use, US prescribing information. [cited Feb 23, 2023]. Available at: https://www.karyopharm.com/wp-content/uploads/2019/07/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf
   Google Scholar
• Stemline Therapeutics BV NEXPOVIO (selinexor) summary of product characteristics. [Last accessed Feb 23, 2023]. Available at: https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf
   Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi: 10.1056/NEJMoa1903455
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546–2554. doi: 10.1182/blood-2018-06-858852
   PubMed Web of Science ®Google Scholar
• Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563–1573. doi: 10.1016/S0140-6736(20)32292-3
   PubMed Web of Science ®Google Scholar
• Richardson PG, Oriol A, Larocca A, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39(7):757–767. doi: 10.1200/JCO.20.02259
   PubMed Web of Science ®Google Scholar
• Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022;9(2):e98–e110. doi: 10.1016/S2352-3026(21)00381-1
   PubMed Web of Science ®Google Scholar
• Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–1642. doi: 10.1016/S1470-2045(20)30525-8
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Quach H, Baz RC, et al. An updated safety and efficacy analysis of venetoclax plus daratumumab and dexamethasone in an expansion cohort of a phase 1/2 study of patients with t(11;14) relapsed/refractory multiple myeloma. Blood. 2022;140(Supplement 1):7261–7263. abstract 3232. doi: 10.1182/blood-2022-163809
   Google Scholar
• Costa LJ, Davies FE, Monohan GP, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021;5(19):3748–3759. doi: 10.1182/bloodadvances.2020004146
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020;34(9):2430–2440. doi: 10.1038/s41375-020-0756-6
   PubMed Web of Science ®Google Scholar
• Mikhael J, Noonan KR, Faiman B, et al. Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor. Clin Lymphoma myeloma Leuk. 2020;20(6):351–357. doi: 10.1016/j.clml.2019.12.026
   Google Scholar
• Nooka AK, Costa LJ, Gasparetto CJ, et al. Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from international myeloma foundation expert roundtable. Clin Lymphoma myeloma Leuk. Clin Lymphoma Myeloma Leukemia. 2022;22(7):e526–e31. doi: 10.1016/j.clml.2022.01.014
   PubMed Web of Science ®Google Scholar
• Machlus KR, Wu SK, Vijey P, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130(9):1132–1143. doi: 10.1182/blood-2016-11-752840
   PubMed Web of Science ®Google Scholar
• Chari A, Florendo E, Mancia IS, et al. Optimal supportive care with selinexor improves outcomes in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(12):e975–e84. doi: 10.1016/j.clml.2021.07.014
   PubMed Web of Science ®Google Scholar
• Auner HW, Gavriatopoulou M, Delimpasi S, et al. Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Am J Hematol. 2021;96(6):708–718. doi: 10.1002/ajh.26172
   PubMed Web of Science ®Google Scholar
• Delimpasi S, Mateos MV, Auner HW, et al. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: subgroup analysis from the BOSTON study. Am J Hematol. 2022;97(3):E83–E6. doi: 10.1002/ajh.26434
   PubMed Web of Science ®Google Scholar
• Oncopeptides Inc. PEPAXTO (melphalan flufenamide) for injection, for intravenous use: prescribing information. [Last accessed Mar 6, 2023]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf
   Google Scholar
• Oncopeptides AB. Pepaxti: EPAR - Production information. [Last accessed Mar 6, 2023]. Available at: https://www.ema.europa.eu/en/documents/product-information/pepaxti-epar-production-information_en.pdf
   Google Scholar
• Richardson PG, Bringhen S, Voorhees P, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020;7(5):e395–e407. doi: 10.1016/S2352-3026(20)30044-2
   PubMed Web of Science ®Google Scholar
• Bobin A, Gruchet C, Guidez S, et al. Novel non-immunologic agents for relapsed and refractory multiple myeloma: a review article. Cancers (Basel). 2021;13(20):5210. doi: 10.3390/cancers13205210
   PubMed Web of Science ®Google Scholar
• Sgherza N, Curci P, Rizzi R, et al. Novel approaches outside the setting of immunotherapy for the treatment of multiple myeloma: the case of melflufen, venetoclax, and Selinexor. Front Oncol. 2021;11:716751. doi: 10.3389/fonc.2021.716751
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. VENCLEXTA (venetoclax tablets), for oral use. Prescribing Information. [Last accessed Feb 23, 2023]. Available at: https://www.rxabbvie.com/pdf/venclexta.pdf
   Google Scholar
• Richardson PG, Trudel S, Quach H, et al. Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. Blood. 2022;140(Supplement 1):1366–1368.
   Google Scholar
• Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol. 2022;9(11):e822–e32. doi: 10.1016/S2352-3026(22)00290-3
   PubMed Web of Science ®Google Scholar
• Lonial S, Abdallah A-O, Anwer F, et al. Iberdomide (IBER) in combination with dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM): results from the anti-B-Cell maturation antigen (BCMA)-exposed cohort of the CC-220-MM-001 trial. Blood. 2022;140(Supplement 1):4398–4400. doi: 10.1182/blood-2022-158180
   Google Scholar
• Lonial S, Richardson PG, Popat R, et al. Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in patients with relapsed/refractory multiple myeloma. Hemasphere. 2021;5(suppl 2):S187.
   Google Scholar
• Richardson P, Sandhu I, Oriol A, et al. Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). IMS 2022. 2022;22:OAB–053. 19th Annual Meeting(abstract book). doi: 10.1016/S2152-2650(22)00326-3
   Google Scholar
• AbbVie. Venclyxto, summary of product characteristics. [Last accessed Feb 23, 2023]. Available at: https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf
   Google Scholar
• Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26(4):595–608. doi: 10.1038/leu.2011.346
   PubMed Web of Science ®Google Scholar
• Chavda SJ, Pocock R, Cheesman S, et al. Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. Br J Haematol. 2020;190(5):e312–e6. doi: 10.1111/bjh.16889
   PubMed Web of Science ®Google Scholar
• Baljevic M, Sborov DW, Lim MY, et al. Optimizing thromboembolism prophylaxis for the contemporary age of multiple myeloma. J Natl Compr Canc Netw. 2022;20(1):91–95. doi: 10.6004/jnccn.2021.7112
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Adekola K, et al. Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(1):67–81.
   PubMedGoogle Scholar
• Khwaja J, Bomsztyk J, Mahmood S, et al. High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis. Blood Cancer J. 2022;12(9):128. doi: 10.1038/s41408-022-00717-2
   PubMed Web of Science ®Google Scholar
• Kfir-Erenfeld S, Asherie N, Grisariu S, et al. Feasibility of a novel Academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis. Clin Cancer Res. 2022;28(23):5156–5166. doi: 10.1158/1078-0432.CCR-22-0637
   PubMed Web of Science ®Google Scholar
• Mailankody S, Matous JV, Chhabra S, et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422–429. doi: 10.1038/s41591-022-02182-7
   PubMedGoogle Scholar
• Sarwar A, Hashim L, Faisal MS, et al. Advances in viral oncolytics for treatment of multiple myeloma - a focused review. Expert Rev Hematol. 2021;14(12):1071–1083. doi: 10.1080/17474086.2021.1972802
   PubMed Web of Science ®Google Scholar
• Vogl DT, Atrash S, Holstein SA, et al. Final results from the first-in-human phase 1/2 study of Modakafusp Alfa, an immune-targeting attenuated cytokine, in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2022;140(Supplement 1):1357–1359. doi: 10.1182/blood-2022-162253
   Google Scholar
• Abramson HN. Recent advances in the applications of small molecules in the treatment of multiple myeloma. Int J Mol Sci. 2023;24(3):2645. doi: 10.3390/ijms24032645
   PubMed Web of Science ®Google Scholar
• Roshandel E, Ghaffari-Nazari H, Mohammadian M, et al. NK cell therapy in relapsed refractory multiple myeloma. Clin Immunol. 2023;246:109168. doi: 10.1016/j.clim.2022.109168
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341
   PubMed Web of Science ®Google Scholar